FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to a method for increasing levels of 2’-deoxyuridine (hereinafter – dUrd) in plasma of a human subject. The method for increasing the concentration of 2’-deoxyuridine (dUrd) in plasma of a human subject includes: a stage (a) of injection of 400 mg/m2 or 500 mg/m2 of 5-fluorouracil (hereinafter – 5-FU) intravenously in the form of a bolus injection to a human subject; after the stage (a), a stage (b) of intravenous injection of 30, 60, 120 or 240 mg/m2 of [6R]-5,10-methylenetetrahydrofolate (hereinafter – 6R-MTHF) intravenously in the form of two bolus injections to the specified human subject, and (c) optional injection of 2400 mg/m2 of 5-FU in the form of continuous infusion simultaneously with the stage (b) or after it.
EFFECT: above-described method allows for significantly increasing dUrd in blood plasma in a joint injection of an equimolar dose of 6R-MTHF with 5-FU compared to a drug.
11 cl, 4 dwg, 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
ADMINISTRATION OF MULTIPLE BOLUSES [6R]-MTHF IN CHEMOTHERAPY BASED ON 5-FLUOROURACIL | 2018 |
|
RU2762596C2 |
[6R]-MTHF-EFFECTIVE FOLATE ALTERNATIVE IN CHEMOTHERAPY BASED ON 5-FLUOROURACIL | 2018 |
|
RU2763934C2 |
METHODS FOR TREATMENT OF COLORECTAL AND METASTATIC COLORECTAL CANCER | 2019 |
|
RU2779535C2 |
STABLE PHARMACEUTICAL COMPOSITION OF 5,10-METHYLENTETRAHYDROFOLATE | 2004 |
|
RU2343923C2 |
REDUCTION METHOD FOR GASTROINTESTINAL TOXICITY CAUSED BY TEGAFUR | 2005 |
|
RU2348409C2 |
THERAPEUTIC COMBINATIONS CONTAINING INHIBITOR OF POLY(ADP-RIBOSE)POLYMERASE | 2005 |
|
RU2361592C2 |
ANTIBODIES TO FGFR2 IN COMBINATION WITH CHEMOTHERAPY IN CANCER TREATMENT | 2018 |
|
RU2797560C2 |
IL-6 RECEPTOR ANTIBODY FOR TREATING JUVENILE IDIOPATHIC ARTHRITIS | 2020 |
|
RU2822089C2 |
METHOD OF TREATING PATIENTS WITH CANCER WITH SEVERE RENAL INSUFFICIENCY | 2017 |
|
RU2727598C2 |
PHOSPHORUS AMIDATE DERIVATIVES OF 5-FLUORO-2'-DEOXYURIDINE APPLICABLE FOR TREATING CANCER | 2012 |
|
RU2614406C2 |
Authors
Dates
2022-07-11—Published
2018-02-09—Filed